Kobayashi Pharmaceutical Co Ltd
TSE:4967
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (23.7), the stock would be worth ¥8 152.63 (42% upside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 16.7 | ¥5 748 |
0%
|
| 3-Year Average | 23.7 | ¥8 152.63 |
+42%
|
| 5-Year Average | 25 | ¥8 614.1 |
+50%
|
| Industry Average | 14.2 | ¥4 882.66 |
-15%
|
| Country Average | 11.5 | ¥3 942.35 |
-31%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| JP |
|
Kobayashi Pharmaceutical Co Ltd
TSE:4967
|
427.3B JPY | 16.7 | 116.9 | |
| FR |
|
L'Oreal SA
PAR:OR
|
201.5B EUR | 23.3 | 32.9 | |
| UK |
|
Unilever PLC
LSE:ULVR
|
93.4B GBP | 10 | 11.3 | |
| IN |
|
Hindustan Unilever Ltd
NSE:HINDUNILVR
|
5.6T INR | 47.4 | 37.6 | |
| UK |
|
HALEON PLC
LSE:HLN
|
31.6B GBP | 12 | 19 | |
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
28.1B USD | 16.9 | -158.1 | |
| DE |
|
Beiersdorf AG
XETRA:BEI
|
15.8B EUR | 20.1 | 16.8 | |
| JP |
|
Kao Corp
TSE:4452
|
2.7T JPY | 13.4 | 22.2 | |
| IN |
|
Godrej Consumer Products Ltd
NSE:GODREJCP
|
1.2T INR | 48.9 | 64.1 | |
| CA |
|
Relevium Technologies Inc
XTSX:RLV
|
12.2B CAD | 552.9 | -4 624.4 | |
| IN |
|
Dabur India Ltd
NSE:DABUR
|
815.9B INR | 42.4 | 43.3 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 8 |
| Median | 11.5 |
| 70th Percentile | 16 |
| Max | 277 515 329.3 |
Other Multiples
Kobayashi Pharmaceutical Co Ltd
Glance View
In the bustling landscape of Japanese business, Kobayashi Pharmaceutical Co., Ltd. stands as an epitome of innovation and tradition. Founded in 1886, this company, steeped in history, has consistently demonstrated a knack for transforming simple consumer needs into thriving business opportunities. Core to its operations is the development, manufacturing, and marketing of consumer healthcare products that subtly blend pharmaceutical expertise with daily convenience. This approach has allowed Kobayashi Pharmaceutical to carve out a distinctive niche, particularly in over-the-counter (OTC) health and personal care products. The company's vast array of products is remarkably diverse, ranging from cooling gel sheets for fevers to herbal medicinal drinks, each crafted with an understanding of consumer pain points and a commitment to well-being. What sets Kobayashi apart in the competitive market is its strategic focus on niche products that serve unmet needs. This laser-sharp business model does more than just bolster its domestic market; it drives its global expansion into key markets in Asia, North America, and Europe. The company's profitability hinges not just on innovation but also on its agile response to the shifting preferences of health-conscious consumers. Driven by a mission to deliver "small but valuable products," Kobayashi’s nimble approach, coupled with an impressive R&D focus, ensures that it remains at the forefront of both consumer satisfaction and shareholder value. Much like a well-crafted Japanese garden, every part of Kobayashi's operation is meticulously designed to function harmoniously, making it a standout player in the global consumer healthcare industry.